February 25, 2022
Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium;
Director, SingHealth Duke-NUS Institute of Biodiversity Medicine (BD-MED);
Deputy Medical Director (Research);
Deputy Director (Global Relations);
Senior Principal Investigator, Institute of Molecular and Cell Biology, Singapore;
Senior Group Leader, Genome Institute of Singapore
Professor Teh Bin Tean obtained his MD (1992) from the University of Queensland, Australia and his PhD (1997) from the Karolinska Institute, Sweden.
Following postdoctoral works at Karolinska Institute, Professor Teh joined the Van Andel Research Institute (VARI), USA in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. In 2007, Professor Teh was appointed as the founding Director of the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010 he received the Singapore Translational Research Investigator Award (STaR) and relocated to Singapore and is currently a full professor in Cancer and Stem Cell Biology (CSCB) Programme at Duke-NUS. He served as the SingHealth Group Director for Translational Research from 2010-2012.
His laboratory focuses on Genomics of Asian-Prevalent Cancers and in the last 5 years have made seminal discoveries in the field including hepatobiliary cancer, herbal carcinogen-related cancer and fibroepithelial tumors of the breast.
He holds Adjunct Professorships at several universities worldwide including Baylor College of Medicine, USA, Nanjing University and Sun Yat-Sen University, China and the Karolinska Institute, Sweden.
Professor Teh has published extensively, with over 400 publications in high impact scientific journals. He is a past and present member of numerous editorial boards for journals including Science Translational Medicine, Lancet Oncology, Cancer Research, Molecular Cancer Therapeutics, International Journal of Cancer. Professor Teh is a recipient of the 2015 Singapore President Science Award and the 2018 AACR (American Association of Cancer Research) Team Science Award.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system